Sign In
Buy OVID
$2.44
-0.0100 (-0.408%)
At Close: Jul 17, 2026
Implied Volatility Surging for Ovid Therapeutics (OVID) Stock Options
01:02pm, Monday, 22'nd Jun 2020
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
Xconomy: Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better
02:27am, Saturday, 20'th Jun 2020
Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy
Ovid Therapeutics (NASDAQ:OVID) Shares Gap Up After Analyst Upgrade
01:24am, Saturday, 20'th Jun 2020
Ovid Therapeutics Inc (NASDAQ:OVID) gapped up before the market opened on Friday after Cantor Fitzgerald raised their price target on the stock from $7.00 to $13.00. The stock had previously closed at
Xconomy: Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
03:33pm, Friday, 19'th Jun 2020
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
12:00pm, Friday, 19'th Jun 2020
Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and
Xconomy: In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo
11:00am, Friday, 19'th Jun 2020
Ten years ago Mark Smith was at MIT doing basic research into the microbiome. Now, as CEO of Finch Therapeutics Group, Smith has hard data to back up his
Deals of the day-Mergers and acquisitions
10:00am, Friday, 19'th Jun 2020
The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Friday:
Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources | MarketScreener
06:36am, Friday, 19'th Jun 2020Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources
06:25am, Friday, 19'th Jun 2020
Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's <4502.T> consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($
Ovid Therapeutics (NASDAQ:OVID) Shares Up 35.7% on Analyst Upgrade
01:24am, Friday, 19'th Jun 2020
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) shot up 35.7% on Thursday after Cantor Fitzgerald raised their price target on the stock from $7.00 to $13.00. Cantor Fitzgerald currently has an overweig
Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources
12:00am, Friday, 19'th Jun 2020
Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources
Xconomy: Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
12:00pm, Thursday, 18'th Jun 2020
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential
M&T Bank Corp Sells 1,668 Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK)
08:12am, Thursday, 18'th Jun 2020
M&T Bank Corp cut its stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 5.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The
Neurocrine Biosciences和武田宣布合作开发和商业化精神疾病潜在治疗药物
12:00am, Thursday, 18'th Jun 2020
(美国商业资讯)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)和武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布一项旨在开
